Interim FDG-PET Imaging in Lymphoma

被引:23
|
作者
Gallamini, Andrea [1 ]
Zwarthoed, Colette [2 ]
机构
[1] A Lacassagne Canc Ctr, Res Innovat & Stat Dept, Nice, France
[2] A Lacassagne Canc Ctr, Nucl Med Dept, Nice, France
关键词
POSITRON-EMISSION-TOMOGRAPHY; B-CELL LYMPHOMA; STAGE HODGKINS LYMPHOMA; PROGRESSION-FREE SURVIVAL; PERIPHERAL T-CELL; EARLY F-18-FDG PET; RESPONSE ASSESSMENT; PROGNOSTIC VALUE; OPEN-LABEL; INTERPRETATION CRITERIA;
D O I
10.1053/j.semnuclmed.2017.09.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma. A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemotherapy treatment, but an increased number of reports have recently been published focusing on the role of iPET in relapsed or refractory lymphoma to predict treatment outcome. Varying patterns of FDG uptake was observed across various lymphoma entities; hence, interpretation of FDG-PET scans should be in the context of the tumor architecture and the prevalence of cellular population, in particular, neoplastic vs non-neoplastic inflammatory cells present in tissue microenvironment. In the second part of the article, the authors reviewed the iPET response adapted clinical trials and the clinical benefits of this strategy compared to standard non PET adapted therapy. In particular, the authors extrapolated the reproducibility of FDG-PET image interpretation and the feasibility of a timely treatment adaptation based on FDG-PET results in daily clinical practice. This is essential for the reader, as the iPET-adapted strategy has become the standard of care in both early- and advanced-stage Hodgkin lymphoma, and, in the future, probably this strategy will be expanded to primary mediastinal B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 50 条
  • [1] Interim FDG-PET/CT for Response Assessment of Lymphoma
    Zeman, Merissa N.
    Akin, Esma A.
    Merryman, Reid W.
    Jacene, Heather A.
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2023, 53 (03) : 371 - 388
  • [2] Interim FDG-PET in lymphoma, a questionable practice in hematology
    Hugo J. A. Adams
    Thomas C. Kwee
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 2014 - 2017
  • [3] Interim FDG-PET in lymphoma, a questionable practice in hematology
    Adams, Hugo J. A.
    Kwee, Thomas C.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (12) : 2014 - 2017
  • [4] FDG-PET in lymphoma
    Michel Meignan
    [J]. Cancer Imaging, 14 (Suppl 1)
  • [5] Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.
    Stefoni, Vittorio
    Broccoli, Alessandro
    Alinari, Lapo
    Ambrosini, Valentina
    Derenzini, Enrico
    Fanti, Stefano
    Fina, Mariapaola
    Gandolfi, Letizia
    Marchi, Enrica
    Pellegrini, Cinzia
    Quirini, Federica
    Zinzani, Pier Luigi
    Baccarani, Michele
    [J]. BLOOD, 2009, 114 (22) : 662 - 662
  • [6] EFFECT OF INSULIN ON FDG-PET IMAGING IN PATIENTS WITH LYMPHOMA
    MINN, H
    KNUUTI, J
    LINDHOLM, P
    BERGMAN, J
    TERAS, M
    RUOTSALAINEN, U
    NUUTILA, P
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (05) : P224 - P224
  • [7] FDG-PET and radiotherapy in lymphoma
    Ricardi U.
    Specht L.
    Versari A.
    Berthelsen A.K.
    [J]. Clinical and Translational Imaging, 2015, 3 (4) : 321 - 330
  • [8] FDG-PET in Hodgkin lymphoma
    Kobe, C.
    Dietlein, M.
    Mauz-Koerholz, C.
    Engert, A.
    Borchmann, P.
    Sabri, O.
    Schober, O.
    Schicha, H.
    Kluge, R.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2008, 47 (06): : 235 - 238
  • [9] FDG-PET in aggressive non Hodgkin lymphoma: the prognostic value of interim evaluation
    Aloj, L.
    Frigeri, F.
    Caraco, C.
    Crisci, S.
    Farese, R.
    Ibello, F.
    Morisco, A.
    Capobianco, G.
    Volzone, F.
    Pinto, A.
    Lastoria, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S692 - S692
  • [10] Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
    Akram Al-Ibraheem
    Farah Anwer
    Malik E. Juweid
    Qaid Ahmed Shagera
    Aysar N. Khalaf
    Shahed Obeidat
    Areen Mansour
    Mohammad Ma’koseh
    Khalid Halahleh
    Imad Jaradat
    Nidal Almasri
    Asem Mansour
    [J]. Scientific Reports, 12